Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in moderate to severe atopic dermatitis extension study
NCT06012812Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Sep 2023; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06012812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012812.